- Home
- MEGL vs GLMD Comparison
MEGL vs GLMD Comparison
Compare MEGL & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | GLMD |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.6M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MEGL | GLMD |
|---|---|---|
| Price | $1.20 | $0.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.0K | ★ 184.4K |
| Earning Date | 12-11-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,296,394.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.74 |
| 52 Week High | $5.52 | $3.61 |
Technical Indicators
Market Signals| Indicator | MEGL | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 35.20 |
| Support Level | $1.16 | $0.95 |
| Resistance Level | $1.34 | $0.99 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.43 | 11.25 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.